Laboratorios Farmaceuticos Rovi, S.A. Overview
Valuation check: ROVI.MC's ROE is 26.43%, above the sector sector average of 11.73%.
Get informed when a big investor buys or sells
+ Follow26.43%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC) currently reports a ROE of 26.43%. That is above the sector sector average of 11.73%. Use the charts on this page to explore Laboratorios Farmaceuticos Rovi, S.A.'s ROE history and peer comparisons.
Laboratorios Farmaceuticos Rovi, S.A.'s ROE of 26.43% is higher than the its sector sector average of 11.73%. That is roughly 125.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Laboratorios Farmaceuticos Rovi, S.A.'s current 26.43% should be judged against industry norms (sector average: 11.73%) and against ROVI.MC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 26.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.73%. From there, open related valuation or income-statement pages for Laboratorios Farmaceuticos Rovi, S.A., and consider following ROVI.MC for alerts when major investors trade the stock.
